Wenyan Xu

838 citations
37 papers · 627 indexed · h-index 14
Topics
Hippo pathway signaling and YAP/TAZ (15 papers)Renal and related cancers (5 papers)Genetic and Kidney Cyst Diseases (5 papers)
Journals
Proceedings of the National Academy of SciencesSHILAP Revista de lepidopterologíaThe EMBO Journal
Partner nations
ChinaUnited StatesMacao

In The Last Decade

Wenyan Xu

35 papers receiving 622 citations

Peers

Wenyan Xu
Comparison fields: 5 of 97
  • Molecular Biology 421
  • Cell Biology 176
  • Cancer Research 113
  • Genetics 61
  • Oncology 57
Replace Miguel Sánchez‐Álvarez with:
Miguel Sánchez‐Álvarez Spain
Yap Ching Chew United States
Jinhyuk Bhin South Korea
Sei Kondo Japan
Gitali Ganguli‐Indra United States
Ya Chun Wu Hong Kong
Carl Ward United Kingdom
Nsrein Ali Finland
Xuguang Chen China
Mohsen Hosseini France
Wenyan Xu relative to Miguel Sánchez‐Álvarez Spain Miguel Sánchez‐Álvarez's profile →
Citations per field
00.5×2.8×
Miguel Sánchez‐Álvarez · 1×
Citations per year

Countries citing papers authored by Wenyan Xu

Since Specialization
Citations

This map shows the geographic impact of Wenyan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenyan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenyan Xu more than expected).

Fields of papers citing papers by Wenyan Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenyan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenyan Xu. The network helps show where Wenyan Xu may publish in the future.

Co-authorship network of co-authors of Wenyan Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Wenyan Xu. A scholar is included among the top collaborators of Wenyan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenyan Xu. Wenyan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 0
3 2
4 2
5 1
6 2
7 7
8 17
9 3
10 16
11 8
12 4
13 43
14 3
15 124
16 4
17 7
18 55
19 20
20 26

About Wenyan Xu

Wenyan Xu is a scholar working on Cell Biology, Molecular Biology and Cancer Research, having authored 37 papers that have together received 627 indexed citations. Recurring topics across this work include Hippo pathway signaling and YAP/TAZ (15 papers), Renal and related cancers (5 papers) and Genetic and Kidney Cyst Diseases (5 papers). The work is most often cited by research in Cell Biology (176 citations), Cancer Research (113 citations) and Molecular Biology (421 citations). Wenyan Xu has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Xianjue Ma, Ying Cao, Xiaowu Xu, Shunrong Ji, Mengqi Liu, Qiangsheng Hu, Wensheng Liu, Xianjun Yu, Qiqing Sun and Zheng Zhang. Their work appears in journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and The EMBO Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026